Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03210909 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics and Metabolism of [14C] BMS-986231 in Healthy Male Participants
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT03210909 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 5 participants.
The verdict
NCT03210909, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
An intravenous infusion in healthy subjects to obtain information about the absorption, metabolism, and excretion (AME) of BMS-986231
Interventions
- DRUG BMS-986231
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-06-22 |
| Est. Completion | 2017-07-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03210909
The ClinicalTrials.gov registry entry for NCT03210909 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BMS-986231 is the first listed.
NCT03210909 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03210909 about?
NCT03210909 is a clinical study titled "Pharmacokinetics and Metabolism of [14C] BMS-986231 in Healthy Male Participants". An intravenous infusion in healthy subjects to obtain information about the absorption, metabolism, and excretion (AME) of BMS-986231
What is the current status of trial NCT03210909?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2017-06-22. Estimated completion is 2017-07-20.
What interventions are being tested in trial NCT03210909?
The interventions under investigation include: BMS-986231 (DRUG).
Who is sponsoring clinical trial NCT03210909?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.